Silence Therapeutics (SLN) Non-Current Deffered Revenue (2023 - 2026)

Silence Therapeutics has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $55.2 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 3.62% year-over-year to $55.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.2 million (up 3.62% YoY) and the FY2025 annual result came in at $55.5 million, up 7.07% from the prior year.
• Non-Current Deffered Revenue held at $55.2 million in Q1 2026 per SLN's latest filing, from $55.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $74.5 million in Q4 2022 and troughed at $51.8 million in Q4 2024.
• A 5-year average of $59.4 million and a median of $55.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue fell 29.17% in 2024, then climbed 7.07% in 2025.
• Over 5 years, Non-Current Deffered Revenue stood at $74.5 million in 2022, then dropped by 1.81% to $73.1 million in 2023, then dropped by 29.17% to $51.8 million in 2024, then gained by 7.07% to $55.5 million in 2025, then fell by 0.43% to $55.2 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $55.2 million, $55.5 million, and $55.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.